Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody

Hara, Yoshitaka; Makita, Masanori; Ishikawa, Tadataka; Saeki, Kyosuke; Yamamoto, Kazuhiko; Imajo, Kento; Shima, Midori; Ieko, Masahiro

doi:10.1007/s00277-012-1600-5

Cited by 16 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both of these disease entities, in addition to other autoimmune conditions, such as Sjogrens' syndrome (SS), Goodpasture's syndrome, myasthenia gravis (MG), Graves disease, and autoimmune hemolytic anemia, have been shown to induce inhibitors [3, 13–15]. Although our patient had a normal factor II (prothrombin) level, the presence of LA has been associated with antibodies against prothrombin, in what is known as lupus anticoagulant hyperprothrombinemia syndrome (LAC-HPS; [39–41]). …”

Section: Discussionmentioning

confidence: 90%

An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

Zeichner

Harris

Turner

et al. 2013

Case Reports in Hematology

View full text Add to dashboard Cite

Introduction. Despite its low incidence, acquired factor VIII inhibitor is the most common autoantibody affecting the clotting cascade. The exact mechanism of acquisition remains unclear, but postpartum patients, those with autoimmune conditions or malignancies, and those with exposure to particular drugs appear most susceptible. There have been several case reports describing acquired FVIII inhibitors in patients receiving interferon alpha for HCV treatment and in patients being treated for HIV. To our knowledge, this is the first case of a patient with HCV and HIV who was not actively receiving treatment for either condition. Case Presentation. A 57-year-old Caucasian male with a history of HIV and HCV was admitted to our hospital for a several day history of progressively worsening right thigh bruising and generalized weakness. CTA of the abdominal arteries revealed large bilateral retroperitoneal hematomas. Laboratory studies revealed the presence of a high titer FVIII inhibitor. Conclusion. Our case of a very rare condition highlights the importance of recognizing and understanding the diagnosis of acquired FVIII inhibitor. Laboratory research and clinical data on the role of newer agents are needed in order to better characterize disease pathogenesis, disease associations, genetic markers, and optimal disease management.

show abstract

Section: Discussionmentioning

confidence: 90%

An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

Zeichner

Harris

Turner

et al. 2013

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…The association between plasma levels of paraprotein and prolonged clotting factors, particularly aPTT, has been described previously . Abnormal aPTT was related to the presence of LA and abnormal clotting factors (VIII, IX, and XI) resulting in a paraneoplastic syndrome related to MM, as these results normalized after chemotherapy and transplant .…”

Section: Discussionmentioning

confidence: 98%

Hematuria as the first sign of multiple myeloma

Alves

Moreno

Rodrigues

et al. 2017

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…16,20,27,39,44,49,51 In 33% of the patients (29 out of 87 patients) bleeding was preceded by an infection (mostly viral, adenovirus in approximately half of these cases). 11,21,23,25,28,32,35,36,39,47,48,[52][53][54]61,73 In three cases (3%) LA-HPS was associated with lymphoma, 17,40,63 in one case with multiple myeloma, 17 and in two cases LA-HPS was suspected to be drug induced (quinidine in one case and phenytoin in the other). 29,59 In 10% of cases (nine out of 87 cases) no underlying diagnosis was identified that could have been associated with the development of LA-HPS (''idiopathic'').…”

Section: Underlying Diagnosismentioning

confidence: 99%

Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature

Mulliez

Keyser

Verbist

et al. 2014

Lupus

View full text Add to dashboard Cite

Lupus anticoagulant-hypoprothrombinemia syndrome (LA-HPS) is a rare acquired disorder caused by prothrombin antibodies. The disease is most common in the pediatric age group (<16 years), and more prevalent in women. There are well-established clinical diseases associated with LA-HPS, most notably systemic lupus erythematosus (SLE) and viral infections. The clinical manifestation of LA-HPS varies greatly in severity and it may cause severe life-threatening bleeding diathesis. LA-HPS is to be suspected when a patient presents with bleeding and a prolonged activated partial thromboplastin and prothrombin time, in combination with a lupus anticoagulant. The diagnosis is confirmed in the laboratory by identification of reduced prothrombin levels. There are no standardized recommendations for treatment of the hemorrhage associated with the syndrome; corticosteroids are used as first-line treatment. This review summarizes what is currently known about the pathogenesis, clinical features, diagnosis, treatment and prognosis of LA-HPS, and presents two case reports.

show abstract

Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody

Cited by 16 publications

References 9 publications

An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

Hematuria as the first sign of multiple myeloma

Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature

Contact Info

Product

Resources

About